Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Crohn's Disease and Intestinal Transplantation

P. Drastich, M. Oliverius,

. 2017 ; 35 (1-2) : 127-133. [pub] 20170201

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc17013277

BACKGROUND: Most patients with Crohn's disease (CD) require one or more operations during their lifetime. Repeated resections and surgical complications may result in short gut in a subset of patients, typically those with extensive small bowel disease or a penetrating CD phenotype. The effects of short bowel syndrome (SBS) can range in seriousness from mild to life-threatening advanced intestinal failure. Worldwide, CD is the second leading indication for intestinal transplantation (ITx) in SBS, but the overall incidence of ITx is quite low. Key Messages: Currently, total parenteral nutrition (TPN) is the preferred treatment option for patients with SBS because of its superior survival outcome. However, TPN can fail from loss of venous access due to catheter-associated thromboses, recurrent catheter-related blood stream infections, or intestinal-failure-associated liver dysfunction. Three types of transplantations are available for CD patients - small bowel alone, liver plus small bowel and multivisceral, which includes other intra-abdominal organs. An abdominal wall transplant is required in case of abdominal wall defects or lack of free intra-abdominal space. The current 5-year survival rate of 54% following ITx of the isolated small bowel appears worse than that associated with TPN. However, outcomes are substantially improving because of surgical and technical advances and progress in medical therapy. On the other hand, ITx carries the risk of both complications (e.g., rejection, infections, and post transplant lymphoproliferative disorders) and adverse events associated with immunosuppression. CD recurrence has been reported in a few patients, but this primarily histologic recurrence might not be of great clinical importance. CONCLUSIONS: ITx has become a well-established treatment for those who fail on TPN and who have life-threatening complications. Fortunately, it concerns only a small proportion of CD patients, but it does offer reasonable survival and quality of life. Primary management of patients with small bowel failure should be provided by a center experienced in medical intestinal rehabilitation, nutrition, and transplantation of other solid organs.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17013277
003      
CZ-PrNML
005      
20170428121437.0
007      
ta
008      
170413s2017 sz f 000 0|eng||
009      
AR
024    7_
$a 10.1159/000449093 $2 doi
035    __
$a (PubMed)28147371
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Drastich, Pavel $u Hepatogastroenterology Department, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
245    10
$a Crohn's Disease and Intestinal Transplantation / $c P. Drastich, M. Oliverius,
520    9_
$a BACKGROUND: Most patients with Crohn's disease (CD) require one or more operations during their lifetime. Repeated resections and surgical complications may result in short gut in a subset of patients, typically those with extensive small bowel disease or a penetrating CD phenotype. The effects of short bowel syndrome (SBS) can range in seriousness from mild to life-threatening advanced intestinal failure. Worldwide, CD is the second leading indication for intestinal transplantation (ITx) in SBS, but the overall incidence of ITx is quite low. Key Messages: Currently, total parenteral nutrition (TPN) is the preferred treatment option for patients with SBS because of its superior survival outcome. However, TPN can fail from loss of venous access due to catheter-associated thromboses, recurrent catheter-related blood stream infections, or intestinal-failure-associated liver dysfunction. Three types of transplantations are available for CD patients - small bowel alone, liver plus small bowel and multivisceral, which includes other intra-abdominal organs. An abdominal wall transplant is required in case of abdominal wall defects or lack of free intra-abdominal space. The current 5-year survival rate of 54% following ITx of the isolated small bowel appears worse than that associated with TPN. However, outcomes are substantially improving because of surgical and technical advances and progress in medical therapy. On the other hand, ITx carries the risk of both complications (e.g., rejection, infections, and post transplant lymphoproliferative disorders) and adverse events associated with immunosuppression. CD recurrence has been reported in a few patients, but this primarily histologic recurrence might not be of great clinical importance. CONCLUSIONS: ITx has become a well-established treatment for those who fail on TPN and who have life-threatening complications. Fortunately, it concerns only a small proportion of CD patients, but it does offer reasonable survival and quality of life. Primary management of patients with small bowel failure should be provided by a center experienced in medical intestinal rehabilitation, nutrition, and transplantation of other solid organs.
650    _2
$a dospělí $7 D000328
650    _2
$a Crohnova nemoc $x komplikace $x chirurgie $7 D003424
650    _2
$a lidé $7 D006801
650    _2
$a imunosupresivní léčba $x škodlivé účinky $7 D007165
650    _2
$a nemoci střev $x etiologie $x chirurgie $7 D007410
650    _2
$a tenké střevo $x transplantace $7 D007421
650    _2
$a parenterální výživa úplná $7 D010289
650    _2
$a kvalita života $7 D011788
650    _2
$a syndrom krátkého střeva $x etiologie $x chirurgie $7 D012778
650    _2
$a míra přežití $7 D015996
650    _2
$a výsledek terapie $7 D016896
650    _2
$a mladý dospělý $7 D055815
655    _2
$a časopisecké články $7 D016428
700    1_
$a Oliverius, Martin
773    0_
$w MED00173707 $t Digestive diseases (Basel, Switzerland) $x 1421-9875 $g Roč. 35, č. 1-2 (2017), s. 127-133
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28147371 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170413 $b ABA008
991    __
$a 20170428121758 $b ABA008
999    __
$a ok $b bmc $g 1199742 $s 974055
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 35 $c 1-2 $d 127-133 $e 20170201 $i 1421-9875 $m Digestive diseases $n Dig Dis $x MED00173707
LZP    __
$a Pubmed-20170413

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace

Nahrávání dat ...